Kidney Transplant Failure — Kidney Transplantation and Renal and Myocardial Perfusion
Citation(s)
Al-Mallah MH, Hachamovitch R, Dorbala S, Di Carli MF Incremental prognostic value of myocardial perfusion imaging in patients referred to stress single-photon emission computed tomography with renal dysfunction. Circ Cardiovasc Imaging. 2009 Nov;2(6):429
Bosmans JL, Ysebaert DK, Verpooten GA Chronic allograft nephropathy: what have we learned from protocol biopsies? Transplantation. 2008 Apr 15;85(7 Suppl):S38-41. doi: 10.1097/TP.0b013e318169c5d0. Review.
Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000 Mar 1;35(3):681-9.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 Sep 23;351(13):1296-305. Erratum in: N Engl J Med. 2008;18(4):4.
Green MA, Hutchins GD Positron emission tomography (PET) assessment of renal perfusion. Semin Nephrol. 2011 May;31(3):291-9. doi: 10.1016/j.semnephrol.2011.05.008.
Hollenberg NK, Sandor T Vasomotion of renal blood flow in essential hypertension. Oscillations in xenon transit. Hypertension. 1984 Jul-Aug;6(4):579-85.
Jerosch-Herold M, Wilke N, Stillman AE Magnetic resonance quantification of the myocardial perfusion reserve with a Fermi function model for constrained deconvolution. Med Phys. 1998 Jan;25(1):73-84.
Palmer RM, Ferrige AG, Moncada S Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987 Jun 11-17;327(6122):524-6.
Kidney Transplantation and Renal and Myocardial Perfusion
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
